Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma

Abstract

IntroductionWe examined the sustainability of the intraocular pressure (IOP)-lowering efficacy of travoprost (0.004%) ophthalmic solution in subjects with normal tension glaucoma (NTG).MethodsTravoprost ophthalmic solution was given once daily at 9 PM to subjects with newly diagnosed NTG or with NTG who had not received any ocular hypotensives within the previous 30 days. IOP was measured at three time points (9 AM, 1 PM, and 5 PM) at baseline and week 12 visits, and at one time point (9 AM) at week 4 and week 8 visits. Conjunctival hyperemia, superficial punctate keratopathy, and other adverse events were evaluated during the observation period.ResultsThirty subjects (12 males and 18 females; mean age 65.6 years) from 32 subjects enrolled were included in the efficacy analysis. The mean IOPs (±standard deviation) of 16.6 ± 1.4, 15.7 ± 1.8, and 15.7 ± 2.2 mmHg at 9 AM, 1 PM, and 5 PM, respectively, at baseline reduced significantly to the mean IOPs of 13.0 ± 1.8, 12.7 ± 1.8, and 12.8 ± 1.6 mmHg, respectively, at week 12 (P < 0.0001 for every time point). Together with the mean IOPs of 13.4 ± 1.9 mmHg at week 4 and 13.2 ± 1.9 mmHg at week 8, the pooled IOP during the observation period for up to 12 weeks showed a statistically and clinically significant reduction of IOP at 9 AM. (3.4 mmHg or 20.3% reduction from baseline, P < 0.0001). There were no adverse events leading to treatment discontinuation.ConclusionThis multi-center collaborative study suggests that IOP-lowering efficacy of travoprost ophthalmic solution persists during the day at the clinically relevant level in subjects with NTG.FundingAlcon Japan Ltd.Trial registrationUniversity Hospital Medical Information Network, UMIN ID: 000011621.Electronic supplementary materialThe online version of this article (doi:10.1007/s12325-016-0297-6) contains supplementary material, which is available to authorized users.

Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal‐tension glaucoma: the randomized phase II study

“…Although the drug treatment period and the races varied between the ROCK inhibitor trials, sovesudil evidently showed lower rates of conjunctival hyperaemia, specifically 17.5% (7/ 40 subjects in low-dose group) and 24.4% (10/41 subjects in high-dose group). Additionally, the ocular AEs in this present trial are comparable to those of similar studies on b-blockers and PGA drugs with NTG patients (Tsumura et al 2012;Naito et al 2016). The dropout rate in the current study was relatively low, at ~8.4% (10/ 119 patients), with only 5 patients dropping out due to adverse ocular events (classified as mild or moderate).…”

“…2012; Naito et al. 2016). The dropout rate in the current study was relatively low, at ~8.4% (10/119 patients), with only 5 patients dropping out due to adverse ocular events (classified as mild or moderate).…”

Ocular hypotensive effects of prostaglandin analogs in Japanese patients with normal-tension glaucoma: a literature review

“…Twenty-seven articles were included in the final analysis (11 articles in Category 1 and 25 articles in Category 2; Figure 1 ). In Category 1, there were three articles for latanoprost, 15 – 17 two articles for travoprost, 18 , 19 one article for bimatoprost, 20 five articles for tafluprost 21 – 25 ( Table 1 ), and 0 articles for unoprostone. In Category 2, the number of articles for each PGA was as follows: 14 for latanoprost, 15 , 16 , 26 – 37 seven for travoprost, 18 , 19 , 26 , 38 – 41 three for bimatoprost, 20 , 26 , 40 seven for tafluprost, 21 – 23 , 25 , 26 , 39 , 40 and 0 articles for unoprostone ( Table 2 ).…”